論文

査読有り
2016年8月

The Efficacy of Rituximab in High-risk Renal Transplant Recipients

ACTA MEDICA OKAYAMA
  • Motoo Araki
  • ,
  • Koichiro Wada
  • ,
  • Yosuke Mitsui
  • ,
  • Risa Kubota
  • ,
  • Takashi Yoshioka
  • ,
  • Yuichi Ariyoshi
  • ,
  • Yasuyuki Kobayashi
  • ,
  • Masashi Kitagawa
  • ,
  • Katsuyuki Tanabe
  • ,
  • Hiroshi Sugiyama
  • ,
  • Jun Wada
  • ,
  • Masami Watanabe
  • ,
  • Toyohiko Watanabe
  • ,
  • Katsuyuki Hotta
  • ,
  • Yasutomo Nasu

70
4
開始ページ
295
終了ページ
297
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.18926/AMO/54507
出版者・発行元
OKAYAMA UNIV MED SCHOOL

Although graft survival following renal transplantation (RTx) has improved, outcomes following highrisk RTx are variable. Preexisting antibodies, including donor-specific antibodies (DSA), play an important role in graft dysfunction and survival. We have designed a study to investigate the safety and efficacy of anti-CD20 monoclonal antibodies (rituximab) in high-risk RTx recipients. Major eligibility criteria include: 1) major and minor ABO blood group mismatch, 2) positive DSA. Thirty-five patients will receive 200 mg/body of rituximab. The primary endpoint is the incidence of B cell depletion. This study will clarify whether rituximab is efficacious in improving graft survival in high-risk RTx recipients.

Web of Science ® 被引用回数 : 1

リンク情報
DOI
https://doi.org/10.18926/AMO/54507
Web of Science
https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=JSTA_CEL&SrcApp=J_Gate_JST&DestLinkType=FullRecord&KeyUT=WOS:000384748600011&DestApp=WOS_CPL
URL
http://orcid.org/0000-0003-1468-5170
ID情報
  • DOI : 10.18926/AMO/54507
  • ISSN : 0386-300X
  • ORCIDのPut Code : 43365884
  • Web of Science ID : WOS:000384748600011

エクスポート
BibTeX RIS